Artelo Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing and commercializing therapeutic agents that interact with the endocannabinoid system. The company's portfolio of drug candidates features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is currently undergoing Phase 1b/2a clinical trials for the management of anorexia linked to cancer. Another promising candidate is ART12.11, a synthetic cannabidiol cocrystal being explored for its potential in treating inflammatory bowel disease and post-traumatic stress disorder (PTSD). Additionally, ART26.12, a fatty acid binding protein 5 inhibitor, is in development to address breast and prostate cancer, neuropathic and nociceptive pain, and various anxiety disorders, including PTSD. The company, initially incorporated in 2011 as Reactive Medical, Inc., was rebranded as Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California.